熱門資訊> 正文

Guardant Health以高达1.5亿美元收购以色列医疗科技MetaSight

2026-02-20 23:41

Guardant Health(GH) 0

Guardant Health (GH) has acquired MetaSight Diagnostics for $59M upfront and up to $90M in milestone payments.
The Israeli startup is known for developing early cancer and liver fibrosis detection tests that use liquid biopsy technology.
Guardant will maintain MetaSight's team in Rehovot.
MetaSight was founded in 2020 as a collaboration between between Israeli healthtech and life sciences investment fund aMoon and Computer Science and Biology Professor Tomer Shlomi at the Technion.

More on Guardant Health

Guardant Health, Inc. (GH) Q4 2025 Earnings Call Transcript
Guardant Health: Look For Explosive Revenue Growth Ahead
Guardant Health: Shield Colorectal Cancer Screening To Sustain Growth
Guardant Health outlines 27%–30% revenue growth for 2026 while expanding Shield and oncology portfolio
Guardant Health guides Q4 and FY25 revenue above consensus

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。